O. O. Dmytrenko, I. V. Dmytrenko, Zh. M. Minchenko, I. S. Diahil


To study the associative relation of polymorphic HLA gene variants and BCR/ABL1 transcript types in patients with chronic myeloid leukemia (CML) 87 CML patients were examined. 42 patients had e13a2 BCR/ABL1 transcript and 45 patients had e14a2 BCR/ABL1 transcript. The prevalence of the genes allelic variants of major histocompatibility complex was analyzed and the association coefficients for the disease risk depending on the presence of certain types of BCR/ABL1 transcripts were calculated.
Unconditional markers of increased risk of CML (HLA-DRB1*11) and markers of resistance to CML (HLA-A*03) were highlighted. The allele frequencies of HLA-A*03, HLA-A*68, HLA-B*08, HLA-B*15, HLA-B*40, HLA-DRB1*04, DQB1*06 were significantly reduced and allele frequencies of HLA-DRB1*12 and DRB1*11 were increased in patients with the e13a2 transcript compared to healthy people. The allele frequencies of HLA-A*03, HLA-A*11, HLA-B*08, HLA-B*14, HLA-B*40, HLA-DRB1*04 and DQB1* 03 were significantly reduced and the allele frequency of HLA-DRB1*11 was significantly increased in patients with e14a2 transcript compared to healthy persons. Thus, the individual analysis of the complex of fusion proteins e13a2 and e14a2 and HLA alleles in CML patients could indicate the additive effect of both molecular structures joint carrier for CML developing risk.


chronic myeloid leukemia; BCR/ABL1 transcripts; allelic polymorphism; HLA systems


Jabbour E. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring / E. Jabbour, H. Kantarjian // Am. J. Hematol. – 2016. – Vol. 91. – P. 252–265.

Dmytrenko I. V. Assessment of response to imatinib therapy in patients with chronic myeloid leukemia with e13a2 and e14a2 transcripts of BCR/ABL1 gene / I. V. Dmytrenko, V. G. Fedorenko, T. Y. Shlyakhtychenko et al // Probl. Radiac. Med. Radiobiol. – 2015. – Sep. 20. – Р. 328–340.

Hanfstein B. Distinct characteristics of e13a2 versus e14a2 BCR'ABL1 driven chron' ic myeloid leukemia under first'line therapy with imatinib / B. Hanfstein, M. Lauseker, R.Hehlmann et al. // Haematologica. – 2014. – Vol. 99, №. 9. – P. 1441–1447.

Lucas C. M. Chronic myeloid leukemia patients with the e13a2 BCR'ABL fusion tran' script have inferior responses to imatinib compared to patients with the e14a2 transcript / C. M. Lucas, R. J. Harris, A. Giannoudis et al. // Haematologica. – 2009. – Vol. 94, №. 10. – Р. 1362–1367.

Bateman A. Human leukocyte antigenes and cancer: is it in our genes? / A. Bateman, W. Howell // J. Pathology. – 2007. – Vol. 196, № 3. – P. 231–236.

Minchenko J. M. Role of radiosensitivity and radioresistance genetic markers in hematological and cardiovascular disease in persons exposed after the Chornobyl accident / J. M. Minchenko, I. S. Dyagil, O. O. Dmytrenko et al // Probl. Radiac. Med. Radiobiol. – 2013. – Sep. 18.– Р. 220–231.

Matzaraki V. The MHC locus and genetic susceptibility to autoimmune and infectious diseases / V. Matzaraki, V. Kumar, C. Wijmenga, A. Zhernakova // Genome Biol. – 2017. – Vol. 18, №. 1. – 76. Published online 2017 Apr 27. doi: 10.1186/s13059-017-1207-1.

Ureshino H. Allelic polymorphisms of KIRs and HLAs predict favorable responses to tyrosine kinase inhibitors in CML / H. Ureshino, T. Shindo, H. Kojima et al. // Cancer Immunol. Res. – 2018. Published online 2018 Apr 25. doi: 10.1158/2326-6066.CIR-17-0462.

Mundhad S. Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11) / S. Mundhada, R. Luthra, P. Cano // Cancer. – 2004. – Vol. 4. – P. 4–25.

Chomczynski P. Single step method of RNA isolation by acid and guanidinum thiocyanate-phenol-chloroform extraction / P. Chomczynski, N. Sacchi // Anal. Biochem.–– 1987. — Vol. 162, № 1. — P. 156–159.



  • There are currently no refbacks.

Copyright (c) 2019 O. O. Dmytrenko, I. V. Dmytrenko, Zh. M. Minchenko, I. S. Diahil

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.